Published in Cogn Behav Neurol on June 01, 2011
A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol (2016) 2.86
Neuroinflammation and psychiatric illness. J Neuroinflammation (2013) 1.42
Acute onset of focal seizures, psychiatric features and confusion: a case of autoimmune encephalitis? BMJ Case Rep (2012) 0.75
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
De novo mutations in epileptic encephalopathies. Nature (2013) 7.42
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol (2003) 4.44
Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol (2004) 3.56
Anterior temporal lobectomy with amygdalohippocampectomy for mesial temporal sclerosis: predictors of long-term seizure control. J Neurosurg (2013) 3.29
Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res (2006) 3.05
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2008) 2.83
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg (2009) 2.66
The human K-complex represents an isolated cortical down-state. Science (2009) 2.54
Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology (2002) 2.41
Cannabinoids in the Treatment of Epilepsy. N Engl J Med (2015) 2.27
Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. Radiology (2006) 2.22
Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol (2005) 2.16
Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol (2002) 2.15
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol (2003) 1.83
Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med (2003) 1.78
Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci (2003) 1.77
Heterogeneous neuronal firing patterns during interictal epileptiform discharges in the human cortex. Brain (2010) 1.62
High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol (2008) 1.61
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
Health-related quality of life over time since resective epilepsy surgery. Ann Neurol (2007) 1.59
IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J Immunol (2005) 1.56
Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol (2005) 1.56
Race/ethnicity, sex, and socioeconomic status as predictors of outcome after surgery for temporal lobe epilepsy. Arch Neurol (2006) 1.55
Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery (2006) 1.54
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg (2011) 1.52
Epilepsy surgery for children with tuberous sclerosis complex. J Child Neurol (2004) 1.52
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer (2010) 1.50
Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci U S A (2005) 1.48
Selective emotional detachment from family after right temporal lobectomy. Epilepsy Behav (2003) 1.47
Impaired consciousness in temporal lobe seizures: role of cortical slow activity. Brain (2010) 1.44
Slow cortical dynamics and the accumulation of information over long timescales. Neuron (2012) 1.42
The excitable cerebral cortex Fritsch G, Hitzig E. Uber die elektrische Erregbarkeit des Grosshirns. Arch Anat Physiol Wissen 1870;37:300-32. Epilepsy Behav (2009) 1.42
Neuroinflammation and psychiatric illness. J Neuroinflammation (2013) 1.42
Do tubers contain function? Resection of epileptogenic foci in perirolandic cortex in children with tuberous sclerosis complex. Epilepsia (2010) 1.39
Mechanisms of glioma-associated neovascularization. Am J Pathol (2012) 1.39
Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology (2004) 1.39
Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. Pediatrics (2006) 1.37
Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR Am J Neuroradiol (2002) 1.36
Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. Cancer Res (2002) 1.36
Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res (2012) 1.34
The epilepsy phenome/genome project. Clin Trials (2013) 1.32
Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. Am J Hum Genet (2003) 1.26
Receptor protein tyrosine phosphatase alpha is essential for hippocampal neuronal migration and long-term potentiation. EMBO J (2003) 1.25
The treatment of nonepileptic seizures: historical perspectives and future directions. Epilepsia (2004) 1.24
Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav (2010) 1.23
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol (2010) 1.22
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys (2008) 1.17
A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav (2003) 1.15
Epilepsy: is localization-related epilepsy a progressive disorder? Maybe... Nat Rev Neurol (2009) 1.14
Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol (2008) 1.14
Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer (2004) 1.13
Seizure outcome after resection of supratentorial cavernous malformations: a study of 168 patients. Epilepsia (2007) 1.12
Cyst with a mural nodule tumor of the brain. Cancer Imaging (2012) 1.11
Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol (2009) 1.11
Multimodal imaging of repetition priming: Using fMRI, MEG, and intracranial EEG to reveal spatiotemporal profiles of word processing. Neuroimage (2010) 1.09
Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation (2013) 1.08
MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia (2002) 1.08
Efficacy of vagus nerve stimulation over time: review of 65 consecutive patients with treatment-resistant epilepsy treated with VNS > 10 years. Epilepsy Behav (2011) 1.07
Kluver-Bucy syndrome, hypersexuality, and the law. Neurocase (2009) 1.06
Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol (2005) 1.06
Detection of epileptogenic cortical malformations with surface-based MRI morphometry. PLoS One (2011) 1.05
Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging. Technol Cancer Res Treat (2004) 1.04
Degree of handedness and cerebral dominance. Neurology (2006) 1.04
Current treatments of epilepsy. Neurology (2005) 1.04
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex. Epilepsia (2014) 1.04
Evidence for cortical reorganization of language in patients with hippocampal sclerosis. Brain (2007) 1.02
HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol (2010) 1.01
Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. Cancer Res (2011) 1.00
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J Cell Physiol (2004) 1.00
Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol (2015) 1.00
Pediatric language mapping: sensitivity of neurostimulation and Wada testing in epilepsy surgery. Epilepsia (2007) 0.99
Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol (2010) 0.99
Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug. Int J Oncol (2006) 0.99
Epilepsy and anxiety. Epilepsy Behav (2003) 0.98
Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatr (2011) 0.98
Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys (2010) 0.97
Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review. Cogn Behav Neurol (2013) 0.97
Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol (2009) 0.96
INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors. Clin Cancer Res (2007) 0.96
Default mode network abnormalities in idiopathic generalized epilepsy. Epilepsy Behav (2012) 0.96
The case for assessing cannabidiol in epilepsy. Epilepsia (2014) 0.96
Imaging inflammation in a patient with epilepsy due to focal cortical dysplasia. J Neuroimaging (2011) 0.96
Psychotropic effects of antiepileptic drugs. Epilepsy Curr (2005) 0.96
Right ventromedial prefrontal lesions result in paradoxical cardiovascular activation with emotional stimuli. Brain (2006) 0.95
Sequential then interactive processing of letters and words in the left fusiform gyrus. Nat Commun (2012) 0.95
Endometrial carcinoma with cerebellar metastasis: a case report and review of the literature. J Neurooncol (2002) 0.95
Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer (2011) 0.95
Psychosis in epilepsy patients. Epilepsia (2007) 0.95
Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro Oncol (2013) 0.95